Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers
| Autor: | Shi Wen Jiang, Jinping Li, E. Nickolas Gilbert, Hongyuan Zhou, Tracy Tipton, Qiang Li, Bin Wang, Guo Shao, Brahma N. Singh |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Ovarian Neoplasms
Cancer Research Histone deacetylase 5 biology HDAC11 Histone deacetylase 2 Antineoplastic Agents General Medicine medicine.disease Article Histone Deacetylases Endometrial Neoplasms Histone Deacetylase Inhibitors Histone Non-histone protein Oncology Acetylation medicine biology.protein Cancer research Animals Humans Female Histone deacetylase Ovarian cancer |
| Zdroj: | Future Oncology. 7:1415-1428 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Histone deacetylases (HDACs) remove acetyl groups from lysine residues of histones and the deacetylation allows for tighter electrostatic interactions between DNA and histones, leading to a more compact chromatin conformation with limited access for transactivators and the suppression of transcription. HDAC mRNA and protein overexpression was observed in endometrial and ovarian cancers. Numerous in vitro studies have shown that HDAC inhibitors, through their actions on histone and nonhistone proteins, are able to reactivate the tumor suppressor genes, inhibit cell cycle progression and induce cell apoptosis in endometrial and ovarian cancer cell cultures. Results from mouse xenograft models also demonstrated the potency of HDAC inhibitors as anticancer reagents when used as single agent or in combination with classical chemotherapy drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|